In this issue:
Tocilizumab for giant cell arteritis
Tofacitinib vs tocilizumab in RA
Infliximab for refractory uveitis due to Behçet disease
Hypogammaglobulinemia after rituximab for RA
Anti-TNF-α for JIA-associated uveitis
Tocilizumab in early polymyalgia rheumatica
Family history and response to TNF inhibitors in spondyloarthritis
Comorbidities and therapeutic persistence of biological agents in RA
Serum golimumab levels in inflammatory joint diseases
Hepatitis B virus reactivation during biological therapy
Please login below to download this issue (PDF)